free hit counter


Access to Innovation


TECHNOLOGY VENTURING SERVICES, S.L.U ( everis Group, subsidiary of the NTT Data Group) to collaborate in consulting services to transfer innovative technologies of Japanese SMEs and start-ups to European and North American markets.


News Release

Japan Technology Group, an international broker of technology-based intellectual property (based in Tokyo, Japan; CEO: Taro Yaguchi), has established a business partnership with
i-deals Innovation & Technology Venturing Services (based in Madrid, Spain; CEO: Ángel Sánchez Díaz), a consulting company of technology transfer and commercialisation support in European, North American and Latin American markets.

The parent company of i-deals, everis, has recently been acquired by NTT Data in January 2014. i-deals operates to create value for innovative technological start-ups, SMEs and universities in different markets supporting their commercialisation and internationalisation. To achieve this objective i-deals combines its deep understanding of technology with the knowledge of the market needs and dynamics of the different sectors it works in (medical, biotechnology, chemical processes, nano science, energy, etc.).

JTG serves as an international broker of technology over 10 years, matching international companies and untapped promising Japanese innovations. JTG has an extensive network of key stakeholders in the technology licensing field in Japan, which differentiates JTG from technology transfer companies in other countries.

Through the partnership with i-deals, JTG will accelerate consulting business to support technology transfer of Japanese universities and research institutions and help start-ups and SMEs to expand their market into European and North American regions. JTG and i-deals will take advantage of each other’s expert network in Japan and Europe/North America and will jointly undertake different activities collaborating with public organisations for R&D and investigation projects.

JTG will target URA (Research Administrators) of universities and TLO (Technology Licensing Organization) which aim to collaborate with overseas companies and start-ups with the objective of expanding their markets outside of Japan, JTG and i-deals will provide seminars based on their knowledge and expertise of market value analysis.



i-deals overview


Tech Partners

JTG News

Wellspring Announces Japan Technology Group as a Channel Partner for Japan Market

Wellspring Worldwide, the leader in software for technology transfer and corporate innovation management, today appointed Japan Technology Group (JTG) as a strategic channel partner in Japan.

Japan Technology Group as member of the International Consortium has been awarded a contract to research and identify European industrial technologies of high cooperation and business potential for Japan.


TECHNOLOGY VENTURING SERVICES, S.L.U ( everis Group, subsidiary of the NTT Data Group)

What people are saying about JTG

“JTG has proven to be very dependable and as advertised, they are extremely well connected to the research community in Japan.  Their core expertise and approach to doing business are in alignment with our objectives.  As a result, we have been able to establish several strategic relationships and collaboration opportunities.”

University of Hawai‘i
Larry Cutshaw
Director Business Development, Office of the Vice President for Research and Innovation


Sample list of corporations which provide technological needs to JTG. 
(Listed in alphabetical order)

Abiogen Pharma, Ablynx, AERAS Global TB Vaccine Foundation, Affitech USA, Agilent Technologies, Air Products & Chemicals, Alfresa Pharma Corporation, Amgen, Anatech Ltd., AntiCancer, Inc., Aphton, ApoLife, Applera Corporation, Ariston Pharmaceuticals, ArtiSoft, Astellas Pharma, Astellas Pharma Europe, AstraZeneca, AstraZeneca K.K.(Japan R&D), AstraZeneca Pharmaceuticals LP, Athena Diagnostics, BASF AG, Bausch & Lomb AG, Bayer HealthCare LLC, Bayer Crop Science, Beacon Pharmaceuticals, BioInvent International AB, Biological Targets, BioMarin, Biomira, Biotech Park, Biovail, Biovitrum Biopharmaceuticals, birchbob, Boehringer Ingelheim, Boehringer Laboratories, BTG plc, Cargill, Cenamps, Central Life Sciences, Chemicon International, Chiron, Cima Labs, Clean Diesel Technologies, Colgate Palmolive Company, Corium International, Curacyte AG, Debiopharm SA & Debioinnovation, Diversa, DuPont, Dyax, Dynogen, ebadu ventures limited, Ecolab, Elementis, Eli Lilly, F.Hoffman-La Roche, Fresenius Kabi, Gaylord Chemical Corp., GE Healthcare, Genentech, General Mills, Genetrix, Genzyme, GlaxoSmithKline, Goodlife Healthcare, GSK Consumer Healthcare, Helsinn Healthcare, Hitachi Americas, HSS Ventures, iCo Therapeutics, Immune Control, Innovata plc, InterMolecular, Invitrogen Corporation, Johnson & Johnson, Juelich Fine Chemicals, KMG Japan, Kubota Research Associates, Kuros Biosurgery, LabCorp, Lampire Biological Laboratories, Leiras Finland, Life Technologies Corporation, L’Oreal USA Products, Lorus Therapeutics, March Plasma Systems, Maxygen, MedImmune, Menarini Biotech, Merck & Co, Merck Frosst Canada, Merz, Microsoft Corporation, Milliken Chemical, Millipore, Millwrights, Monsanto, MOSAID Technologies Incorporated, NichiBei Bio, NineSigma, Novartis Consumer Healthcare, NovaThera, Novo Nordisk A/S, Novus Biologicals, NTTC, Office of Law Enforcement Techn. Commercialia, OM THANIKAI INDUSTRIES, Pain Therapeutics, Pfizer Consumer Healthcare, Pfizer, Inc, Pharmacopeia, philogene, Pierre Fabre SA, Plant Biosciences (PBL), PPG Industries, Praxair, Procter & Gamble, ProCyte Corporation, Promega, QLT, RCT BioVentures, Reckitt Benckiser , Replizyme, Roche, Sanofi-Aventis, Sanofi-Pasteur, SC Johnson & Son, SemBioSys Genetics,, Signet Laboratories, SingVax, SkinMedica, SSL International, StoneBridge Pharma, Sunesis, Technic, The Dow Chemical Company, Two River, Upstate USA, Vincogen Corp., Vishay Intertechnologies, Ward Industries, Ward Industries, WellGen, WorldTech, Wyeth Pharmaceuticals,, Zephyr Sciences, Zobele



April, 2010 [company of the everis Group (established in 1996)]

*The everis Group is a fully-owned subsidiary of the NTT Group since January 2014

Av. Manoteras, 52, 28050 Madrid, Spain

Market value analysis, technology transfer and commercialisation


support of innovative technology initiatives in European, North American and Latin American markets


JTG web

i-deals web

everis Group web




Name of the company:








Business model:


Related links

Contact / Inquiries

Japan Technology Group, Inc.
Tel: +81-3-5298-6552